Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment

Despite the development of cancer biomarkers and targeted therapies, most cancer patients do not have a specific biomarker directly associated with effective treatment options. We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ precision oncology 2024-12, Vol.8 (1), p.278-10
Hauptverfasser: Wang, Suming, Zota, Victor, Vincent, Melanie Y., Clossey, Donna, Chen, Jian Jenny, Cieslewicz, Michael, Watnick, Randolph S., Mahoney, James, Watnick, Jing
Format: Artikel
Sprache:eng
Schlagworte:
631/67/1857
692/4028/67/1059/602
692/53/2422
Biomarkers
Biopsy
Brief Communication
Cancer Research
Cancer therapies
Fatty acids
Gene Therapy
Glioma
Human Genetics
Internal Medicine
Medical prognosis
Medicine
Medicine & Public Health
Oncology
Ovarian cancer
Patients
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite the development of cancer biomarkers and targeted therapies, most cancer patients do not have a specific biomarker directly associated with effective treatment options. We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). Our studies identified CD36 and CD47 as dual biomarkers that can be used as patient stratifying tools and prognostic biomarkers for VT1021 treatment.
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-024-00774-9